## **PATENT**



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	) Prior Group Art Unit: 1632
KINZLER et al.	) Prior Examiner: S. Priebe
Continuation of	)
Serial No. 08/390,474	)
Filed: October 1, 2001	) Atty. Dkt. No. 01107.00193

For: AMPLIFICATION OF MDM2 GENE OF HUMAN MDM2 GENE IN HUMAN TUMORS

## INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents Washington, D.C. 20231

Sir:

Pursuant to the duty of good faith and candor as set forth in 37 C.F.R. § 1.56(a) Applicant submits herewith a Form PTO 1449. Since these documents were previously cited in Application Serial No. 08/390,474 no copies are being supplied herewith.

Applicant respectfully requests that the Examiner consider and enter these documents into the file of the above-identified application. No fee is believed to be due to ensure consideration and entry of the cited documents by the Examiner. However, if a fee is deemed necessary, the Commissioner is authorized to charge our Deposit Account No. 19-0733.

Respectfully submitted,

Sarah A. Kagan

Registration No. 32,141

Dated: October 1, 2001

BANNER & WITCOFF, LTD. 1001 G Street, N.W., 11<sup>th</sup> Floor Washington, D.C. 20001

TEL: (202) 508-9100 FAX: (202) 508-9299

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute fo	bstitute for form 1449A/PTO		Complete if Known			
				Application Number	TBA/Continuation of 08/390,474	
INFORMATION DISCLOSURE			LOSURE	Filing Date	September 28, 2001	
STATEMENT BY APPLICANT		First Named Inventor	KINZLER et al.			
				Prior Group Art Unit	1632	
(use as many sheets as necessary)				Prior Examiner Name	S. Priebe	
Sheet	1	of	2	Attorney Docket Number	01107.00193	$\overline{J}$

	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS			
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
	Fakharzadeh, et al., "Tumorigenic Potential Associated with Enhanced Expression of a Gene Tht is Amplified in a Mouse Tumor Cell Line", The EMBO Journal, 10(6):1565-1569 (1991)			
	Hinds, et al., "Mutant p53 DNA Clones From Human Colon Carcinomas Cooperate with Ras in Transforming Primary Rat Cells: A Comparison of the "Hot Spot" Mutant Phenotypes", Cell Growth & Differentiation, 1:561-580			
	Romkes, et al., "Cloning and Expression of cDNA for Multiple Members of the Human Cytochrome P450IIC Subfamily", Biochemistry, 30(13):3247-3255 (1991)			
	Momand, et al., "The MDM2 Oncogene Product Forms a Complex with the p53 Protein and Inhibits p53-Mediated Transactivation," Cell, 69:1237-1245 (1992)			
	Oliner, et al., "Amplification of a Gene Encoding a p53-Associated Protein in Human Sarcomas", Nature, 358:80-83 (1992)			
	Ladanyi, et al., "MDM2 Gene Amplification in Metastatic Osteosarcoma", Cancer Research, 53:2231-2234 (1993)			
	Oliner, et al., "Oncoprotein MDM2 Conceals the Activation Domain of Tumour Supprssor p53", Nature, 362(6423):857-860 (1993)			
	Cahilly, et al., "Molecular Analysis and Chromosomal Mapping of Amplified Genes Isolated from a Transformed Mouse 3T3 Cell Line", Somatic Cell and Molecular Genetics, 13(3):235-244 (1987)			
	Hodgson, Exp. Opin, Ther, Pat., 5(5), 1995, 459-468			
	Uhlmann et al., <u>Chem. Rev.</u> , 90(4), 1990, 544-584			
	Culver et al., <u>TIG</u> , 10(5), 1994, 174-178			
	Leach, et al., "p53 Mutation and MDM2 Amplification in Human Soft Tissue Sarcomas", <u>Cancer Research</u> , 53:2231-2234 (1993)			
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  Fakharzadeh, et al., "Tumorigenic Potential Associated with Enhanced Expression of a Gene Tht is Amplified in a Mouse Tumor Cell Line", The EMBO Journal, 10(6):1565-1569 (1991)  Hinds, et al., "Mutant p53 DNA Clones From Human Colon Carcinomas Cooperate with Ras in Transforming Primary Rat Cells: A Comparison of the "Hot Spot" Mutant Phenotypes", Cell Growth & Differentiation, 1:561-580 (1990)  Romkes, et al., "Cloning and Expression of cDNA for Multiple Members of the Human Cytochrome P450IIC Subfamily", Biochemistry, 30(13):3247-3255 (1991)  Momand, et al., "The MDM2 Oncogene Product Forms a Complex with the p53 Protein and Inhibits p53-Mediated Transactivation," Cell, 69:1237-1245 (1992)  Oliner, et al., "Amplification of a Gene Encoding a p53-Associated Protein in Human Sarcomas", Nature, 358:80-83 (1992)  Ladanyi, et al., "MDM2 Gene Amplification in Metastatic Osteosarcoma", Cancer Research, 53:2231-2234 (1993)  Oliner, et al., "Oncoprotein MDM2 Conceals the Activation Domain of Tumour Supprssor p53", Nature, 362(6423):857-860 (1993)  Cahilly, et al., "Molecular Analysis and Chromosomal Mapping of Amplified Genes Isolated from a Transformed Mouse 3T3 Cell Line", Somatic Cell and Molecular Genetics, 13(3):235-244 (1987)  Hodgson, Exp. Opin, Ther. Pat., 5(5), 1995, 459-468  Uhlmann et al., Chem. Rev., 90(4), 1990, 544-584  Culver et al., "1G, 10(5), 1994, 174-178  Leach, et al., "p53 Mutation and MDM2 Amplification in Human Soft Tissue Sarcomas", Cancer Research,		

Date	
Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known TBA/Continuation of 08/390,474 **Application Number** INFORMATION DISCLOSURE Filing Date September 28, 2001 STATEMENT BY APPLICANT First Named Inventor KINZLER et al. Group Art Unit 1632 (use as many sheets as necessary) **Examiner Name** S. Priebe 2 01107.00193 Attorney Docket Number Sheet of

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
		Narayanan et al., <u>Oncogene</u> , 1992, 7(3), 553-561		
		Levine et al., <u>Nature</u> , 351, 1991, 453-456		
		Marshall, <u>Science</u> , 269, 1995, 1050-1055		
_		Stein et al., <u>Science</u> , 261, 1993, 1004-1012		
•		Wu-Pong, <u>Pharm. Tech.</u> , 18, 1994, 102-114		
		Miller et al., <u>FASEB</u> , 9, 1995, 190-199		
		Rojanasakul, <u>Ad. Drug. Del. Rev.</u> , 18 (1996), 115-131		
		Miller, <u>J. Med. Chem.</u> , 36(14):1423-1437, 1993		
-				

Examiner		Date	
		Considered	
Signature	•		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.